A recombinant HSV-2 virus, its application and preparation method
By constructing recombinant HSV-2 viruses with missing or reduced US5 and UL24 genes, the problems of drug resistance and insufficient immune response in existing HSV-2 treatments have been solved, achieving high immunogenicity and tumor-killing effects.
Patent Information
- Application Number
- CN202611113760.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing drugs for treating HSV-2 infection cannot eliminate the virus latent in the ganglia, and long-term use can easily lead to drug resistance. Existing vaccines cannot mimic the natural infection process and cannot induce a broad immune response.
Recombinant HSV-2 viruses were constructed by deleting or reducing the function of the US5 and UL24 genes using bacterial artificial chromosome systems, CRISPR/Cas9 gene editing systems, or kinase systems to prepare HSV-2 vaccines and oncolytic viruses with high immunogenicity.
Recombinant HSV-2 virus exhibits high biosafety and immunoprotective effects, can induce large syncytial formation, significantly inhibit tumor growth, and has a killing effect on a variety of tumor cells.
Smart Images

Figure CN123107939A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a recombinant HSV-2 virus, its uses and preparation method, and more specifically, to a recombinant HSV-2 virus, its modification, construction and preparation process, and its use as an HSV-2 vaccine and oncolytic virus. Background Technology
[0002] Herpes simplex virus type 2 (HSV-2) is the main pathogen of genital herpes. Once infected, it remains latent for life and reactivates periodically. As of 2016, approximately 491 million people aged 15-49 worldwide had HSV-2. Furthermore, HSV-2 increases the risk of HIV infection and transmission by three to four times. Currently, treatment for HSV-2 infection mainly relies on nucleoside analogues, such as acyclovir and valacyclovir. While these drugs can inhibit viral replication, shorten the course of the disease, and reduce the frequency of relapses, they cannot eliminate the viral reservoir latent in nerve ganglia, and long-term use carries the risk of drug resistance.
[0003] Therefore, it is particularly important to develop a vaccine strategy that can mimic the natural infection process, present the full spectrum of viral antigens, and induce a broad immune response. Summary of the Invention
[0004] In view of the shortcomings of the prior art, the purpose of this invention is to provide a recombinant HSV-2 virus that has good immunogenicity while ensuring safety.
[0005] In view of this, in a first aspect, the present invention provides a recombinant HSV-2 virus, wherein the gene functions of the US5 and UL24 genes of the recombinant HSV-2 virus are lost or reduced.
[0006] The recombinant HSV-2 virus of the present invention has high biocompatibility, strong immunogenicity and good immune protection effect. At the same time, the recombinant HSV-2 virus can induce the formation of larger syncytia at the cellular infection level and exhibits good killing effect on a variety of tumor cells, and can significantly inhibit the growth of subcutaneous tumors in nude mice.
[0007] In some specific implementations, the US5 and UL24 genes of the recombinant HSV-2 virus are deactivated.
[0008] In some specific embodiments, the nucleotide sequence of the US5 gene is shown in SEQ ID NO.1, and / or the nucleotide sequence of the UL24 gene is shown in SEQ ID NO.2.
[0009] In some specific implementations, the recombinant HSV-2 virus satisfies at least one of the following characteristics: It retains its replication ability and its virulence has weakened.
[0010] In a second aspect, an HSV-2 vaccine is provided, characterized in that the vaccine comprises the aforementioned recombinant HSV-2 virus as an antigen.
[0011] In some specific implementations, the HSV-2 vaccine is used for intramuscular, intranasal, oral, subcutaneous, intradermal, and vaginal immunization.
[0012] Thirdly, the above-mentioned recombinant HSV-2 virus is provided for use in the preparation of vaccines or oncolytic viruses.
[0013] Fourthly, a viral vector is provided, including the recombinant HSV-2 virus as described above.
[0014] In some specific implementations, the viral vector also includes an antitumor component.
[0015] Fifthly, a method for preparing recombinant HSV-2 virus is provided, comprising: modifying HSV-2 virus using a bacterial artificial chromosome system, a CRISPR / Cas9 gene editing system, or a granule system to cause the gene functions of the US5 and UL24 genes of HSV-2 virus to be lost or reduced. Attached Figure Description
[0016] Figure 1 Figure A shows the double-deletion HSV-2 modification method; Figure B shows the plaque formation after HSV-2 ΔUS5ΔUL24 BAC transfection; Figure C shows the PCR identification of HSV-2 ΔUS5ΔUL24.
[0017] Figure 2 In the table, A represents the weight monitoring results (g) of the immunized mice; B represents the disease symptom score of the immunized mice, ranging from 0 to 5 points, with symptoms gradually worsening.
[0018] Figure 3 In the diagram, A represents the experimental protocol; B represents the body weight (g) of mice after intracranial injection; and C represents the survival rate of mice after intracranial injection.
[0019] Figure 4 In the middle, A represents the serum HSV-2 gB IgG level of immunized mice, and the vertical axis represents OD. 450 Value; B represents the serum HSV-2 gD-specific IgG level of immunized mice, with the ordinate being OD. 450 value.
[0020] Figure 5In the figure, AB represents the body weight (g) and disease score (0-5 points, with symptoms gradually worsening) of mice after vaginal challenge; CD represents the HSV-2 gene content in the spinal cord and cervical tissue of mice after vaginal challenge.
[0021] Figure 6 In the diagram, A represents the HSV-2 gene copy number in brain tissue; B represents the HSV-2 gene copy number in spinal cord tissue.
[0022] Figure 7 AC represents the body weight (g), disease score (0-4 points, with symptoms gradually worsening), and survival rate of the immunized guinea pigs, respectively; DF represents the HSV-2 gene copy number (ICP0, TK, gB) in the spinal cord of the immunized guinea pigs.
[0023] Figure 8 In the middle, A represents the HSV-2 gB-specific IgG level in the serum of immunized guinea pigs, and the vertical axis represents OD. 450 Value; B represents the HSV-2 gD-specific IgG level in the serum of immunized guinea pigs, with the ordinate being OD. 450 value.
[0024] Figure 9 To evaluate the neutralizing effect of HSV-2-specific antibodies in the serum of immunized guinea pigs.
[0025] Figure 10 In the table, AB represents the body weight (g) and disease symptoms (0-4 points, gradually worsening) of immunized guinea pigs after vaginal challenge; C represents the viral titer level in vaginal samples after vaginal challenge of immunized guinea pigs; and D represents the HSV-2 gene copy number in the spinal cord of immunized guinea pigs after vaginal challenge.
[0026] Figure 11 In the graph, A represents the size of the subcutaneous tumor in the euthanized nude mouse; B represents the weight of the nude mouse after subcutaneous tumor inoculation; C represents the tumor volume change curve after intratumoral injection of oncolytic virus; D represents the weight of the subcutaneous tumor; and E represents the tumor inhibition rate of the oncolytic virus. Detailed Implementation
[0027] The present invention will be described in detail below with reference to specific implementation schemes and embodiments, thereby making the advantages and various effects of the present invention more clearly apparent. Those skilled in the art should understand that these specific implementation schemes and embodiments are for illustrative purposes only and are not intended to limit the present invention.
[0028] The "range" disclosed in this application is defined by a lower limit and an upper limit. A given range is defined by selecting a lower limit and an upper limit, which define the boundaries of the particular range. The range defined in this way can include or exclude endpoints and can be arbitrarily combined; that is, any lower limit can be combined with any upper limit to form a range.
[0029] In this application, unless otherwise stated, the numerical range "ab" represents a shortened representation of any combination of real numbers from a to b, where a and b are both real numbers. For example, the numerical range "0-5" indicates that all real numbers between "0-5" have been listed herein, and "0-5" is merely a shortened representation of these numerical combinations. Furthermore, when a parameter is described as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.
[0030] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions. Unless otherwise specified, all technical features and optional technical features of this application can be combined to form new technical solutions.
[0031] Unless otherwise specified, all steps in this application may be performed sequentially or randomly, preferably sequentially. For example, the method includes steps (a) and (b), indicating that the method may include steps (a) and (b) performed sequentially, or it may include steps (b) and (a) performed sequentially. For example, the mention that the method may also include step (c) indicates that step (c) may be added to the method in any order. For example, the method may include steps (a), (b), and (c), or it may include steps (a), (c), and (b), or it may include steps (c), (a), and (b), etc.
[0032] The following describes embodiments of this application. The embodiments described below are exemplary and are only used to explain this application, and should not be construed as limiting this application. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Reagents or instruments used, unless otherwise specified, are all conventional products that can be obtained commercially.
[0033] In a first aspect, the present invention provides a recombinant HSV-2 virus in which the gene functions of the US5 and UL24 genes are lost or reduced.
[0034] The recombinant HSV-2 virus of the present invention has high biocompatibility, strong immunogenicity and good biocompatibility. At the same time, the recombinant HSV-2 virus can induce the formation of larger syncytia at the cellular infection level and exhibits good killing effect on a variety of tumor cells, and can significantly inhibit the growth of subcutaneous tumors in nude mice.
[0035] In this invention, the term "loss of or reduced gene function" means that a gene is unable to encode a protein, or its ability to encode a protein is reduced, or the encoded protein does not possess its corresponding biological function. For example, loss of or reduced gene function of the US5 gene means that the US5 gene is unable to encode the US5 protein, or its ability to encode the US5 protein is reduced, or it is unable to encode a protein with the biological function of the US5 protein.
[0036] In this invention, HSV-2 can be any strain of HSV-2 in the art. Exemplarily, the HSV-2 referred to in this invention can be HSV-2 strain G (KU310668.1), MS strain, HG52 strain (KU310668.1; NC_001798.2), strain 186, and other strains and their derivatives. All of the above strains can be used to construct recombinant HSV-2 viruses by deleting or reducing the gene function of the US5 and UL24 genes.
[0037] In this invention, the US5 gene can be any US5 gene related to HSV-2 in the art, and a nucleotide sequence with an identity of 80%, 90%, 95%, or 99% or higher. The identity calculation can be performed using conventional methods in the art. For example, US5 can be a gene with Genebank accession numbers KU310668.1:149299..149577 (HSV-2 G strain), Z86099.2:140287..140565, or NC_001798.2:140291..140569 (HSV-2 HG52 strain).
[0038] Specifically, the nucleotide sequence of the US5 gene can be the nucleotide sequence described in SEQ ID NO.1: atggatcggtatgccgttcggacctgggggattgtgggaatcctcgggtgtgctgctgttggggccgcacccaccggccccgcgtccgatacaacaaacgcgaccgcacgcctccccacgcaccccccactcatccgttcc gggggctttgccgtccccctcatcgtgggggggctgtgtctcatgattctggggatggcgtgtctactcgaggtcctgcgtcgcctgggtcgcgagttggcgaggtgctgcccccacgcgggccaatttgccccatga (seq ID NO.1).
[0039] Furthermore, it can be a nucleotide sequence that has 80%, 90%, 95%, or 99% or more identity with the nucleotide sequence shown in SEQ ID NO.1.
[0040] In this invention, the UL24 gene can be any UL24 gene related to HSV-2 in the art, and a nucleotide sequence with an identity of 80%, 90%, 95%, or 99% or higher. For example, UL24 can be the gene with Genebank accession numbers KU310668.1:50009..50854 (HSV-2 G strain), Z86099.2:47902..48747, or NC_001798.2:47941..48786 (HSV-2 HG52 strain).
[0041] Specifically, the nucleotide sequence of the UL24 gene can be the nucleotide sequence described in SEQ ID NO.2: atggctaggacgggacgccgcgcggccgtcggtaggcccgctcgcacgagcagcctgaccgaacgcaggcgcgtgctgttggccggcgtgagaagccatacccgcttctacaaggcgttcgcccgagaggtgcgggagttcaacgccaccaggatttgtggaacgctgctgacgctgatgagcgggtcgctgcagggtcgctcgctgttcgaggccacgcgcgtcaccttaatatgcgaagtggacctcgggccgcgccgcccagactgcatctgcgtgttcgaattcgccaatgacaaaacgttgggaggtgtgtgcgtcatcctggagctaaagacatgcaaatcgatttcttccggggacacggccagcaaacgcgaacagcggaccacgggcatgaagcagctgcgccactccctgaagctgctgcagtcgctcgcgcctccgggggacaaggtcgtctacctgtgtcctattttggtgtttgtcgcgcagcgtacgctgcgcgtcagccgcgtgacccggctcgtcccgcaaaagatctccggcaacatcaccgcggccgtgcggatgctccaaagcctgtccacgtatgccgtgccgccggaaccgcagacccggcggtcgcggcgccgggtcgccgcgaccgccagaccgcaaaggcccccctccccgacacgtgacccggaaggcacggcgggtcatccggccccaccagagagcgaccccccctccccaggggtcgtaggcgtcgctgcggagggtgggggtgtgcttcagaaaatcgcggcgcttttttgcgtgccggtggccgccaagagcagaccccggaccaaaaccgagtga (SEQ ID NO.2).
[0042] Further, it may be a nucleotide sequence having 80%, 90%, 95%, 99% or more identity with the nucleotide sequence set forth in SEQ ID NO.2.
[0043] In this invention, the loss or reduction of gene function of the US5 and UL24 genes is achieved through the bacterial artificial chromosome (BAC) system, or through methods such as the CRISPR / Cas9 gene editing system or the Cosmid system.
[0044] In one specific implementation, the loss or reduction of gene function of the US5 and UL24 genes is achieved by modifying the ampicillin resistance gene. amp The expression frame was inserted into UL24, and then the kanamycin resistance gene was... kan The expression cassette is replaced with the US5 gene to construct recombinant HSV-2 viruses with UL24 loss of function and US5 complete loss. For example, the construction process is as follows: Figure 1 As shown in Figure A.
[0045] Specifically, the recombinant strain was named HSV-2 ΔUS5ΔUL24, indicating that the US5 gene was completely deleted, 182-281 indicates that the UL24 gene terminates at amino acid 182, and amino acids 182-281 are not expressed.
[0046] In one specific implementation, the recombinant HSV-2 virus strain of the present invention possesses replication capability. The replication capability of the recombinant HSV-2 virus strain is comparable to, slightly weaker than, or reduced compared to the wild-type HSV-2 strain. "Slightly weaker" means there is no significant difference in replication capability compared to the wild-type HSV-2 strain. "Reduced" means there is a significant difference in replication capability compared to the wild-type HSV-2 strain, but it can still replicate relatively well (while fulfilling its biological functions).
[0047] In one specific implementation, the recombinant HSV-2 virus strain of the present invention exhibits reduced virulence. The virulence of the recombinant HSV-2 virus strain is significantly lower than that of the wild-type HSV-2 strain. Reduced viral virulence means that the severity of pathological damage to the host caused by the virus is reduced.
[0048] In one specific embodiment, the recombinant HSV-2 virus strain of the present invention exhibits good immunogenicity. The recombinant HSV-2 virus strain has comparable immunogenicity to the wild-type HSV-2 strain.
[0049] Secondly, the present invention provides an HSV-2 vaccine comprising the above-mentioned recombinant HSV-2 virus as an antigen.
[0050] Furthermore, the vaccine also includes an adjuvant (immune enhancer). Exemplarily, the adjuvant may be an aluminum adjuvant: aluminum hydroxide or aluminum phosphate; the AS01 family (such as that used in GSK's Shingrix shingles vaccine): a liposome system containing MPL (monophosphoryl ester A) and QS-21 (saponin); CpG ODN (CpG oligodeoxynucleotide): a Toll-like receptor 9 (TLR9) agonist; or MF59 or AS03: a squalene-based oil-in-water emulsion.
[0051] Furthermore, the vaccine also includes buffers and / or pH adjusters to maintain antigen conformation. Exemplarily, the buffer may be histidine buffer, citrate buffer, or phosphate buffer. The pH adjuster may be hydrochloric acid (HCl) or sodium hydroxide (NaOH).
[0052] Furthermore, the vaccine also includes stabilizers. For example, sugars (lyophilized protectants): sucrose, trehalose, or sorbitol; amino acids and their salts: L-arginine, glycine; gelatin; recombinant human serum albumin (rHSA); specific divalent cations: magnesium chloride (MgCl2) or calcium chloride (CaCl2).
[0053] Furthermore, the vaccine also includes surfactants: polysorbate 80 (Tween-80) and poloxamer 188.
[0054] Furthermore, the vaccine also includes preservatives, such as 2-phenoxyethanol.
[0055] Furthermore, the vaccine also includes a pharmaceutically acceptable carrier.
[0056] In some specific implementations, the HSV-2 vaccine is used for intramuscular, intranasal, oral, subcutaneous, intradermal, and vaginal immunization.
[0057] Thirdly, the present invention provides the use of the above-mentioned recombinant HSV-2 virus in the preparation of a vaccine. The vaccine is an anti-HSV-2 vaccine.
[0058] This invention provides the use of the above-mentioned recombinant HSV-2 virus in the preparation of oncolytic viruses.
[0059] Fourthly, the present invention provides a viral vector comprising the aforementioned recombinant HSV-2 virus.
[0060] Furthermore, the viral vector also includes antitumor components.
[0061] Furthermore, the antitumor component may be selected from one or more of the following components: cytokines (such as GM-CSF, IL-2, IL-7, IL-12, IL-15, IL-21, IL-24, IFN-γ, TRAIL), chemokines (such as CXCL9, CXCL11, CCL5, CCL19, CCL21), immune checkpoint inhibitors (such as anti-PD-1, PD-L1, CTLA-4, TIM3, LAG3 antibodies or peptides), bispecific antibodies (such as HER2×CD3, FAP×CD3, CD3×PD-L1), suicide genes (such as HSV-TK, Dm-dNK), apoptosis-inducing genes (such as Apoptin, p53), or anti-angiogenic genes (such as HGFK1, mK5, canstatin).
[0062] Fifthly, a method for preparing recombinant HSV-2 virus is provided, comprising: modifying HSV-2 virus using a bacterial artificial chromosome system, a CRISPR / Cas9 gene editing system, or a granule system to cause the gene functions of the US5 and UL24 genes of HSV-2 virus to be lost or reduced.
[0063] In one specific embodiment, the present invention provides a method for preparing recombinant HSV-2 virus, comprising: modifying HSV-2 virus using a bacterial artificial chromosome system to cause the gene functions of the US5 and UL24 genes of HSV-2 virus to be lost or reduced.
[0064] In one specific implementation, the modification of HSV-2 virus using a bacterial artificial chromosome system includes the use of at least one of the following primers: CGCTGCGCGTCAGCCGCGTGACCCGGCTCGTCCCGCAAAAGATCTCCTAATTACCAATGCTTAATCAGTG (SEQ ID NO. 3); GCATACGTGGACAGGCTTTGGAGCATCCGCACGGCCGCGGGTGATGTTGCCGTTCAGGTGGCACTTTTCGGGG (SEQ ID NO. 4); TGACCGCCGCCGGGGGGCGTGCCTGTTGTTTTGGTCTCAATGAGCCATATTCAACGGGA (SEQ ID NO. 5); or GGGGCGATGGGGTGGGGGCAAGGCCAGAAAGGCGAAAAATTAGAAAAACTCATCGAGCAT (SEQ ID NO. 6).
[0065] Example 1: Construction and preparation of recombinant HSV-2 ΔUS5ΔUL24 virus strain Using molecular cloning methods, gene deletion was performed on BAC containing the complete genome of 186 HSV-2 strains, i.e., without affecting... tk Genes (and) UL24 Insertion of ampicillin resistance gene in the case of reverse gene overlap amp Expression box amp The primers for amplification are UL24 -Amp-F:CGCTGCGCGTCAGCCGCGTGACCCGGCTCGTCCCGCAAAAGATCTCCTAATTACCAATGCTTAATCAGTG, UL24 -Amp-R:GCATACGTGGACAGGCTTTGGAGCATCCGCACGGCCGCGGTGATGATGTTGCCGTTCAGGTGGCACTTTTCGGGG; UL24 Gene termination occurs before Ser182, followed by the removal of the kanamycin resistance gene. kan Expression box replacement US5 Gene, replace primer with US5 up-kan-F: TGACCGCCGCCGGGGGGCGTGCCTGTTGTTTTGGTCTCAATGAGCCATATTCAACGGGA, kan- US5 down-R: GGGGCGATGGGGTGGGGGCAAGGCCAGAAAGGCGAAAAATTAGAAAAACTCATCGAGCAT, constructing an HSV-2 BAC with UL24 function loss and complete US5 loss; transfecting the successfully modified BAC into Vero cells to rescue double-deleted HSV-2 cells with GFP fluorescent labeling (e.g., Figure 1 B), this deletion strain was named HSV-2 ΔUS5ΔUL24. PCR identification confirmed that the HSV-2 ΔUS5ΔUL24 modification was successful (e.g., Figure 1 C).
[0066] Example 2: Safety assessment of recombinant HSV-2 virus in a mouse model (1) Mouse animal model (intramuscular or vaginal injection): Female BALB / c mice (15-20 g), twice intramuscularly or vaginally.
[0067] Results: Compared with wild-type HSV-2, the double-deletion virus strain HSV-2 ΔUS5ΔUL24 was safe in mice via intramuscular and vaginal injection. The wild-type virus strain was administered at a dose of 2.5 mg / L. 105 PFU / animal, the dosage for double-deleted virus strain is 1. 10 5 PFU / each or 2.5 10 5 PFU / mouse, in mice with double-deleted virus strains, no weight loss or disease symptoms (such as...) were observed, whether administered intramuscularly or vaginally. Figure 2 ).
[0068] (2) Mouse animal model (intracranial injection): Female BALB / c mice (15-20 g) were intracranially injected with DMEM or different HSV-2, namely wild-type HSV-2, HSV-2 ΔUS5 single deletion virus, and HSV-2 ΔUS5ΔUL24 double deletion virus, at a dose of 10 g. 4 PFU / animal, volume 15 μL / animal, for 14 consecutive days to monitor weight and disease status.
[0069] Results: Mice in the wild-type HSV-2 and HSV-2 ΔUS5 single-deletion virus groups exhibited symptoms such as weight loss, photophobia, disheveled fur, and abnormal behavior on the second day, with a survival rate of 0%. In contrast, mice in the HSV-2 ΔUS5ΔUL24 double-deletion virus group had a 100% survival rate and remained healthy, without exhibiting symptoms such as weight loss. Figure 3 ).
[0070] Example 3: Immunogenicity assessment of recombinant HSV-2 virus in a mouse model Immunization regimen: Wild-type HSV-2 at a dose of 2.5 mg / L. 10 5 PFU / animal, double-deleted HSV-2 ΔUS5ΔUL24, dosage is 1. 10 5 PFU / each or 2.5 10 5 PFU / animal, administered twice via intramuscular injection, with an interval of 2 weeks between each injection.
[0071] Results: Intramuscular injection of the HSV-2 ΔUS5ΔUL24 double-deletion attenuated strain induced high levels of specific IgG against gB and gD in mice, with a titer of 1:81000 (e.g., ...). Figure 4 ).
[0072] Example 4: Evaluation of the immunoprotective effect of recombinant HSV-2 virus in a mouse model After the second immunization, wild-type HSV-2 (1 10 6Mice were immunized with PFU / mouse via vaginal challenge. After challenge, the mice were monitored for weight and disease score (0-5 points, with symptoms gradually worsening) daily. The experiment ended after two weeks, and all mice were dissected.
[0073] Results: A second intramuscular injection of HSV-2 ΔUS5ΔUL24 protected mice from infection with wild-type HSV-2, and the HSV-2 gene was undetectable in the spinal cord, the site of HSV-2 latency (e.g., Figure 5 ).
[0074] Example 5: Detection of viral genes of recombinant HSV-2 virus in mouse tissues and organs Mouse experimental protocol: 2 mmol / L HSV-2 ΔUS5ΔUL24 virus strain and 2 mmol / L HSV-2 wild-type virus strain were injected intramuscularly, respectively. 10 6 PFU / mouse, 50 μL injected into each leg. Mice were dissected on days 2, 4 and 8 after intramuscular injection, and different tissues and organs were collected. The genome was extracted after grinding and HSV-2 gene copy number in each tissue and organ was detected by qPCR.
[0075] Results: Following HSV-2 ΔUS5ΔUL24 inoculation, the HSV-2 gene was almost undetectable in key neural tissues such as the brain and spinal cord, indicating that HSV-2 ΔUS5ΔUL24 was rapidly eliminated after inoculation (e.g., Figure 6 ).
[0076] Example 6: Evaluation of the safety, immunogenicity, and immunoprotective effect of recombinant HSV-2 virus in a guinea pig model. Guinea pig animal model: female Hartley guinea pig (200-300 g).
[0077] Immunization regimen: Wild-type HSV-2 was administered at a dose of 1... 10 7 PFU / animal, the dosage for double-deleted virus strain is 1. 10 5 PFU / each, 1 10 6 PFU / each or 1 10 7 PFU / animal, two intramuscular injections, three weeks apart.
[0078] 1. Safety evaluation Results: Intramuscular injection of HSV-2 ΔUS5ΔUL24 was safe for guinea pigs compared to wild-type HSV-2. The wild-type virus strain was used at a dose of 1... 10 7 PFU / animal, the dosage of double-deleted virus strain was 1... 10 5PFU / each, 1 10 6 PFU / each or 1 10 7 PFU / guinea pig. No weight loss or disease symptoms were observed in any of the three doses of double-deletion virus strain immunization groups. After two intramuscular injections, the guinea pigs were dissected, and the presence of HSV-2 in the spinal cord was examined. The results showed that the HSV-2 gene (ICP0, TK, gB) was detectable in all wild-type HSV-2 injection groups, while the HSV-2 gene (ICP0, TK, gB) was not detectable in all double-deletion virus strain injection groups. Figure 7 ).
[0079] 2. Immunogenicity assessment Results: Intramuscular injection of HSV-2 ΔUS5 ΔUL24 induced high levels of specific IgG against gB and gD in guinea pigs (e.g., Figure 8 Intramuscular injection of HSV-2 ΔUS5ΔUL24 can effectively induce the production of HSV-2-specific neutralizing antibodies (e.g. Figure 9 ).
[0080] 3. Immunoprotection assessment experiment After the second immunization, wild-type HSV-2 (1×10⁻⁶) was used. 6 After vaginal challenge with PFU / guinea pigs, the weight and disease score of the guinea pigs were monitored daily (0-4 points, with symptoms gradually worsening). The experiment ended after two weeks, and all guinea pigs were dissected.
[0081] Results: Intramuscular injection of HSV-2 ΔUS5ΔUL24 effectively protected guinea pigs from infection with wild-type HSV-2, and the HSV-2 gene was undetectable in the spinal cord (e.g., Figure 10 ).
[0082] Example 7: Evaluation of the efficacy of recombinant HSV-2 virus oncolytic virus Animal model: nude mouse Tumor implantation: Each nude mouse was subcutaneously inoculated with 200 µL of HeLa cell suspension (cell number 1×10⁻⁶). 6 ).
[0083] Inoculation protocol: Tumor growth and mouse status were continuously monitored. Inoculation with the virus began when the tumor volume reached 70-100 mm³. Each mouse received a subcutaneous intratumoral injection of 100 µL of viral fluid (wild-type HSV-2 or HSV-2 ΔUS5ΔUL24) or culture medium (negative control group), administered every other day for a total of three injections. Each injection dose was 5 × 10⁻⁶. 5 PFU.
[0084] Results: Compared with wild-type HSV-2, mice inoculated with HSV-2 ΔUS5ΔUL24 did not develop related symptoms; and like wild-type HSV-2, HSV-2 ΔUS5ΔUL24 significantly inhibited the growth of HeLa subcutaneous xenografts in nude mice, recruited macrophages and natural killer cells to the tumor microenvironment, killed subcutaneous tumor cells, and induced anti-tumor immune responses (such as...). Figure 11 ).
[0085] It should be noted that this application is not limited to the above-described embodiments. The above embodiments are merely examples, and any embodiments with the same structure and effect as the technical concept within the scope of this application are included in the technical scope of this application. Furthermore, various modifications that can be conceived by those skilled in the art to the embodiments, and other ways of constructing by combining some of the constituent elements of the embodiments, without departing from the spirit of this application, are also included in the scope of this application.
Claims
1. A recombinant HSV-2 virus, characterized in that, The recombinant HSV-2 virus has lost or reduced gene function in the US5 and UL24 genes.
2. The recombinant HSV-2 virus according to claim 1, characterized in that, The recombinant HSV-2 virus has lost the gene function of the US5 and UL24 genes.
3. The recombinant HSV-2 virus according to claim 1 or 2, characterized in that, The nucleotide sequence of the US5 gene is shown in SEQ ID NO.1, and / or the nucleotide sequence of the UL24 gene is shown in SEQ ID NO.
2.
4. The recombinant HSV-2 virus according to any one of claims 1-3, characterized in that, The recombinant HSV-2 virus satisfies at least one of the following characteristics: It retains its replication ability and its virulence has weakened.
5. An HSV-2 vaccine, characterized in that, The vaccine comprises recombinant HSV-2 virus as an antigen according to any one of claims 1-5.
6. The HSV-2 vaccine according to claim 5, characterized in that, The HSV-2 vaccine is used for intramuscular, intranasal, oral, subcutaneous, intradermal, and vaginal immunization.
7. Use of recombinant HSV-2 according to any one of claims 1-6 as an HSV-2 vaccine or oncolytic virus.
8. A viral vector comprising the recombinant HSV-2 virus according to any one of claims 1-6.
9. The viral vector according to claim 8, characterized in that, The viral vector also includes antitumor components.
10. A method for preparing recombinant HSV-2 virus, comprising: HSV-2 virus can be modified using bacterial artificial chromosome systems, CRISPR / Cas9 gene editing systems, or kinase systems to result in the loss or reduction of gene function of the US5 and UL24 genes of the HSV-2 virus.
